Precision Quantomics

Executive Summary

Precision Quantomics is a pre-clinical biotech company headquartered in Cambridge, MA, that develops quantitative proteomics-based assays and in vitro platforms to improve drug candidate selection and safety prediction. By providing tools to characterize New Approach Methodologies (NAMs), the company aims to reduce reliance on animal models in drug development. Its products enable forecasting of drug metabolism, transport, and toxicity, targeting pharmaceutical, biotech, academic, and diagnostic laboratories. Founded in 2019, Precision Quantomics addresses a critical need for more accurate and human-relevant preclinical testing, potentially accelerating safer drug development and advancing precision medicine. The company's approach leverages high-resolution mass spectrometry and multiplexed proteomics to quantify protein expression and activity in relevant in vitro systems. This allows for early identification of safety liabilities and more predictive ADME (absorption, distribution, metabolism, excretion) profiling. As regulatory agencies increasingly endorse NAMs, Precision Quantomics is well-positioned to capture market share in the growing in vitro toxicology and drug transport assessment space. With an experienced team and proprietary technology, the company has the potential to become a key partner for pharmaceutical companies seeking to reduce attrition rates and replace animal testing. However, as a private, pre-revenue entity, execution risk remains high until commercial traction is achieved.

Upcoming Catalysts (preview)

• Q4 2026Launch of first commercial assay panel for NAM-based toxicity screening70% success
• H1 2027Strategic partnership with top-20 pharmaceutical company for drug transport validation50% success
• Q3 2026Series A funding round to scale platform and expand team60% success